WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005102289) CLARITHROMYCIN EXTENDED RELEASE FORMULATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/102289    International Application No.:    PCT/IN2005/000085
Publication Date: 03.11.2005 International Filing Date: 17.03.2005
IPC:
A61K 9/20 (2006.01), A61K 9/28 (2006.01), A61K 31/7048 (2006.01)
Applicants: LUPIN LIMITED [IN/IN]; 159, CST Road, Kalina, Santacruz (East), Maharashtra, Mumbai 400 098 (IN) (For All Designated States Except US).
JAYANTHI, Suryakumar [IN/IN]; (IN) (For US Only).
RAGHAVAN, Vineeth [IN/IN]; (IN) (For US Only).
BHANDARI, Nilesh [IN/IN]; (IN) (For US Only).
SEN, Himadri [IN/IN]; (IN) (For US Only)
Inventors: JAYANTHI, Suryakumar; (IN).
RAGHAVAN, Vineeth; (IN).
BHANDARI, Nilesh; (IN).
SEN, Himadri; (IN)
Agent: MAJUMDAR, Subhatosh; S. Majumdar & Co., 5, Harish Mukherjee Road, Calcutta 700 025 (IN)
Priority Data:
356/MUM/2004 24.03.2004 IN
Title (EN) CLARITHROMYCIN EXTENDED RELEASE FORMULATION
(FR) FORMULATION A LIBERATION PROLONGEE DE CLARITHROMYCINE
Abstract: front page image
(EN)A pharmaceutical composition for extended release of erythromycin or a derivative thereof. the composition comprises comprising a pharmaceutically effective amount of the drug and about 50% to about 65% by weight of one or more pharmaceutically acceptable polymer(s). The pharmaceutically acceptable polymer(s) are selected from the group comprising polyvinyl pyrrolidine, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, ethyl cellulose, polyvinyl pyrrolidone/polyvinyl acetate copolymers, polyethylene oxide polymers, acrylic acid polymers, methacrylic acid copolymers, natural gums, and derivatives and mixtures thereof.
(FR)La présente invention concerne une composition pharmaceutique permettant la libération prolongée de d'érythromycine ou d'un dérivé de celle-ci. La composition comprend une quantité efficace d'un point de vue pharmaceutique, d'un médicament et d'environ 50 % à environ 65 % en poids d'un ou de plusieurs polymères acceptables d'un point de vue pharmaceutique. Les polymères acceptables d'un point de vue pharmaceutique, sont choisis dans le groupe comprenant polyvinyl pyrrolidine, hydroxypropyl cellulose, hydroxypropylméthyl cellulose, méthylcellulose, éthyl cellulose, copolymères de polyvinyl pyrrolidone/polyvinyl acétate, polymères de polyéthylène oxyde, polymères d'acide acrylique, copolymères d'acide méthacrylique, gommes naturelles et dérivés et mélanges de ceux-ci.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)